Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia

Published:2019-09-11 Issue:11 Volume:28 Page:1529-1533
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Cole Ashley L.¹²^ORCID,Jazowski Shelley A.³⁴^ORCID,Dusetzina Stacie B.⁵⁶^ORCID

Affiliation:

1. Division of Pharmaceutical Outcomes and PolicyUNC Eshelman School of Pharmacy Chapel Hill North Carolina USA

2. Cecil G. Sheps Center for Health Services Research Chapel Hill North Carolina USA

3. Department of Health Policy and ManagementUniversity of North Carolina at Chapel Hill Chapel Hill North Carolina USA

4. Department of Population Health SciencesDuke University School of Medicine Durham North Carolina USA

5. Department of Health PolicyVanderbilt University School of Medicine Nashville Tennessee USA

6. Vanderbilt‐Ingram Cancer Center Nashville Tennessee USA

Funder

Agency for Healthcare Research and Quality

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4893

Reference15 articles.

1. Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

2. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

3. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

4. Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

5. Generic Price Competition For Specialty Drugs: Too Little, Too Late?

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches;Clinical Drug Investigation;2024-01-05

2. Bioequivalence/bioavailability study of a new formulation of imatinib mesylate 100 mg coated tablets versus Glivec® in Brazilian healthy male volunteers in fed state;Revista Brasileira de Cancerologia;2023-12-14

3. Prior Authorization and Association With Delayed or Discontinued Prescription Fills;Journal of Clinical Oncology;2023-12-12

4. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma;JAMA Network Open;2022-06-07

5. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs;Blood Advances;2021-09-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3